{"organizations": [], "uuid": "e6f6b2668266e5bf7f673204e236fbaaad7f187e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180424.html", "section_title": "Archive News &amp; Video for Tuesday, 24 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/lilly-results/drugmaker-eli-lilly-posts-quarterly-profit-idUSL3N1S1464", "country": "US", "domain_rank": 408, "title": "Drugmaker Eli Lilly posts quarterly profit", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.002, "site_type": "news", "published": "2018-04-24T18:33:00.000+03:00", "replies_count": 0, "uuid": "e6f6b2668266e5bf7f673204e236fbaaad7f187e"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/lilly-results/drugmaker-eli-lilly-posts-quarterly-profit-idUSL3N1S1464", "ord_in_thread": 0, "title": "Drugmaker Eli Lilly posts quarterly profit", "locations": [], "entities": {"persons": [{"name": "akankshita mukhopadhyay", "sentiment": "none"}, {"name": "taltz", "sentiment": "none"}, {"name": "sriraj kalluvila", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "bengaluru", "sentiment": "none"}], "organizations": [{"name": "eli lilly and co", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "eli lilly", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " U.S. drugmaker Eli Lilly and Co reported a quarterly profit on Tuesday on higher demand for its newer treatments such as its diabetes drug Trulicity and psoriasis medicine Taltz.\nThe company reported net income of $1.22 billion, or $1.16 per share, in the first quarter ended March 31, compared with a loss of $110.8 million, or 10 cents per share, a year earlier.\nRevenue rose 9 percent to $5.70 billion. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Sriraj Kalluvila)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-04-24T18:33:00.000+03:00", "crawled": "2018-04-25T14:28:09.002+03:00", "highlightTitle": ""}